Overview

Study to Assess the Efficacy and Safety of iNCDSS in Type 2 Diabetes Mellitus Patients

Status:
Not yet recruiting
Trial end date:
2022-06-30
Target enrollment:
Participant gender:
Summary
This is a multi-center, single-blind, parallel group, randomized controlled trial to access the effect and safety of the Artificial Intelligence Assisted Insulin Titration System (iNCDSS) in patients with Type 2 Diabetes Mellitus.
Phase:
N/A
Details
Lead Sponsor:
Shanghai Zhongshan Hospital
Collaborators:
Fifth People's Hospital,Shanghai
Qingpu Central Hospital,Shanghai
Shanghai Fifth People's Hospital
Shanghai Qingpu Central Hospital
Shanghai Xuhui Central Hospital
Xuhui Central Hospital, Shanghai
Treatments:
Insulin
Insulin, Globin Zinc